Biogen revenue rises 6.4 percent on Spinraza demand

(Reuters) - U.S. drugmaker Biogen Inc reported a 6.4 percent rise in quarterly revenue, driven by strong demand for its recently approved spinal muscular atrophy drug, Spinraza.

Biogen revenue rises 6.4 percent on Spinraza demand
Read More


Bagikan Berita Ini